Genzyme/Isis Expand Mipomersen Clinical Trial Program
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Findings from additional mipomersen clinical trials announced by Genzyme and Isis Jan. 12 will aid in the design of a subsequent outcomes trial FDA has requested for the cholesterol-lowering drug candidate
You may also be interested in...
Genzyme Sets Sights On 13 Drug Approvals By 2012; Only 2 Are NMEs
Only two new molecular entities are included in Genzyme's plan for 13 drug approvals between now and 2012, CEO Henri Termeer said during the company's annual analyst and investor day May 7
Solvay's Androgel REMS Proposal May Need More Restrictions - Cmte.
Solvay may need a more restrictive Risk Evaluation and Mitigation Strategy for AndroGel 1% to adequately warn against the danger of secondary transfer of the testosterone gel, according to some members of FDA's Pediatric Advisory Committee
FDA Complete Response Slows Down, But Won't Stop, Lundbeck's Serdolect
Agency comes to same conclusion as advisory committee: the risky schizophrenia drug could get approved if an appropriate patient group is identified.